Recent news on Acamprosate Calcium

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce ...  -  May 23, 2007
PharmaLive.com (press release),...and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients

BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for ...  -  May 21, 2007
PR Newswire (press release),...an angiotensin receptor blocker and diuretic combination product is not indicated for initial therapy; Campral(R)** (acamprosate calcium), a glutamate

Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter ...  -  Apr 24, 2007
PR-Inside.com (Pressemitteilung),...and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients

Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal ...  -  Apr 12, 2007
Drug Newswire (press release),...and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients

Forest Laboratories Announces Rule 144 Sale by Executive Officer  -  Feb 15, 2007
Drug Newswire (press release),...and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients

Forest Laboratories, Inc. Reports Q3'07 Diluted Earnings Per Share ...  -  Jan 16, 2007
Drug Newswire (press release),...and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients

Forest Laboratories Announces Completion of Acquisition of Cerexa ...  -  Jan 12, 2007
PharmaLive.com (press release),...and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients

Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus ...  -  Dec 14, 2006
Drug Newswire (press release),...and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients

Patient Recruitment For Desmoteplase Phase IIB/III Stroke Study ...  Oct 26, 2006
...receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in ... -Medical News Today (press release), Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. ...  Sep 7, 2006
...receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in ... -PR Newswire

Lexapro(R) Demonstrated Significance On Prospectively Defined ...  -  Dec 7, 2006
Medical News Today (press release),...receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R) (acamprosate calcium), indicated in ...

Somaxon Pharmaceuticals Reports 2006 Second Quarter Financial ...  Aug 9, 2006
...nalmefene. The company is also developing a new formulation of acamprosate calcium for the treatment of certain movement disorders. ... -Yahoo! News

Somaxon Pharmaceuticals Reports 2006 Second Quarter Financial ...  Aug 9, 2006
...nalmefene. The company is also developing a new formulation of acamprosate calcium for the treatment of certain movement disorders. -WebWire

Forest Laboratories, Inc. Reports Fiscal First Quarter 2007 ...  Jul 18, 2006
...receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in ... -MSN Money

Forest Announces Federal Court Upholds Lexapro(R) Patent  Jul 13, 2006
...receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral®* (acamprosate calcium), indicated in ... -Yahoo! News

H. Lundbeck A/S and Forest Laboratories, Inc. file lawsuit against ...  Jul 11, 2006
...receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral® (acamprosate calcium), a glutamate ... -WebWire



Somaxon Pharmaceuticals Reports 2006 First Quarter Financial ...  May 10, 2006
...cessation. Finally, the company is developing a new formulation of acamprosate calcium for the treatment of certain movement disorders. ... - Yahoo! News

Forest Laboratories, Inc. Reports Q4'06 Diluted Earnings Per Share ...  Apr 25, 2006
...receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral®* (acamprosate calcium), indicated in ... - Yahoo! News

Forest Laboratories Signs Grants Manager Agreement With Fast Track ...  Apr 19, 2006
...receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral® * (acamprosate calcium), a glutamate ... - Market Wire

Forest Laboratories Fiscal 2007 Guidance  Apr 26, 2006
...receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in ... - Webbolt Business News





Forest and Almirall Announce a Development and Marketing ...  10 Apr 2006
...receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in ... - Finanzen.net

Smoking Causes the Highest Mortality Rate in the US, Accounting ...  Mar 27, 2006
The 2004 approval and 2005 market introduction of acamprosate calcium (Forest Laboratories Campral) for treatment of alcohol dependence and the 2002 ... - Genetic Engineering News

Replidyne and Forest Laboratories Announce Faropenem Medoxomil ...  Feb 13, 2006
...receptor blocker and diuretic combination product indicated for the second- line treatment of hypertension; Campral(R)* (acamprosate calcium), a glutamate ... - PR Newswire,

The CDC estimates 46.2 million Adults in the US Smoke Cigarettes ...  Jan 26, 2006
The 2004 approval and 2005 market introduction of acamprosate calcium (Forest Laboratories Campral) for treatment of alcohol dependence and the 2002 ... - Business Wire

Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share ...  Jan 17, 2006
...receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral(R) * (acamprosate calcium), a glutamate ... - MSN Money

Mylan Laboratories and Forest Laboratories Announce Nebivolol ...  Jan 12, 2006
...receptor blocker and diuretic combination product indicated for the second- line treatment of hypertension; Campral(R) * (acamprosate calcium), a glutamate ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional